MENU

FENC Stock Fennec Pharmaceuticals (FENC, $9.74) RSI Indicator left the overbought zone on October 06, 2025

A.I.dvisor
at Tickeron.com
Loading...
FENC - Fennec Pharmaceuticals
RSI signal
Bearish Trend
Odds of DOWN Trend
Tickeron
RSI signal
Price: $9.74
Daily change: -$0.14 (-1.42%)
Daily volume: 83.9K
Capitalization: $269.2M
Industry: Biotechnology
This is a signal that FENC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 30 similar cases where FENC's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:

FENC in downward trend: price dove below 50-day moving average on October 10, 2025

FENC moved below its 50-day moving average on October 10, 2025 date and that indicates a change from an upward trend to a downward trend. In of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for FENC moved out of overbought territory on October 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on October 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on FENC as a result. In of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FENC turned negative on October 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FENC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FENC broke above its upper Bollinger Band on September 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (52.910) is normal, around the industry mean (24.226). P/E Ratio (64.143) is within average values for comparable stocks, (54.529). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (6.798) is also within normal values, averaging (349.660).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. FENC showed earnings on August 14, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of therapeutic products based on cell adhesion

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
68 TW Alexander Drive
Phone
+1 919 636-4530
Employees
29
Web
https://www.fennecpharma.com